(Refiles to add dropped word “care” in headline; widens distribution of report to additional clients)
(Reuters) – Edwards Lifesciences on Monday said it has agreed to sell its Critical Care products unit to Becton Dickinson in an all-cash transaction valued at $4.2 billion.
With this agreement, California-based Edwards said it is no longer pursuing the previously announced spin-off of the critical care unit.
The medical device maker had said in April that it would spin off its critical care unit at the end of 2024 to concentrate on its larger heart devices business.
The transaction is expected to close by the end of 2024, subject to the satisfaction or waiver of certain closing conditions.
(Reporting by Pratik Jain in Bengaluru; Editing by Tasim Zahid)
